TABLE 4.
Focus | Author(s) | Year | Location |
---|---|---|---|
Cost assessment | Forbes et al. 25 | 2019 | UK |
Mason et al. 28 | 2017 | UK | |
Acceptability | Barrett and Loughman 29 | 2018 | Ireland |
Baker et al. 30 | 2016 | UK | |
Konstantakopoulou et al. 31 | 2014 | UK | |
Clinical impact | Kanabar et al. 32 | 2021 | UK |
Huang et al. 33 | 2020 | Australia | |
Phu et al. 34 | 2020 | Australia | |
Gunn et al. 35 | 2019 | UK | |
Bowes et al. 36 |
2018 | UK | |
Konstantakopoulou et al. 37 | 2018 | UK | |
Ly et al. 38 | 2017 | Australia | |
Ly et al. 39 | 2016 | Australia | |
McAlinden et al. 40 | 2016 | UK | |
El‐Assal et al. 41 | 2015 | UK | |
Roberts et al. 42 | 2015 | UK | |
Keenan et al. 43 | 2015 | UK | |
Ratnarajan et al. 44 | 2015 | UK | |
Ratnarajan et al. 45 | 2013a | UK | |
Bourne et al. 46 | 2010 | UK | |
Park et al. 47 | 2009 | UK | |
Ang et al. 48 | 2009 | UK | |
Lash et al. 49 | 2006 | UK | |
Mixed focus | Wang et al. 50 | 2021 | Australia |
Ford et al. 51 | 2019 | Australia | |
Konstantakopoulou et al. 52 | 2016 | UK | |
Ratnarajan et al. 53 | 2013b | UK | |
Devarajan et al. 54 | 2011 | UK | |
Parkins and Edgar 55 | 2011 | UK | |
Syam et al. 56 | 2010 | UK | |
Sheen et al. 57 | 2009 | UK | |
Henson et al. 58 | 2003 | UK |